ロード中...
Emerging pharmacologic therapies for primary sclerosing cholangitis
PURPOSE OF REVIEW: The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantation, with a median time to transplant of 12–18 years after diagnosis. There are a number of emerging drugs that have the potential to meet this critically unmet need that will be su...
保存先:
| 出版年: | Curr Opin Gastroenterol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5646688/ https://ncbi.nlm.nih.gov/pubmed/28257308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOG.0000000000000352 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|